None

Vismodegib For Treatment Of Patients With Basal Cell Carcinoma

According to results from the pivotal Phase II ERIVANCE BCC trial, up to 2,000 individuals suffering from advanced basal cell carcinoma (aBCC) in the UK could significantly benefit from a once a day p...

[News] Vismodegib effective against advanced basal-cell carcinoma

Two studies have shown that vismodegib—a hedgehog pathway inhibitor—is effective against advanced forms of basal-cell carcinoma (BCC).

Vismodegib effective for multiple basal cell tumors

A new study has found vismodegib to be effective in shrinking and preventing the formation of basal cell carcinoma (BCC) in patients with basal cell nevus syndrome (BCNS).

Vismodegib team wins Drug Discovery of the Year award

The British Pharmacological Society proudly announces that its first annual Drug Discovery of the Year award has been won by the discovery team developing vismodegib for the treatment of basal cell ca...

Roche’s vismodegib named Drug Discovery of the Year by the British Pharmacological Society

Roche today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society.

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer...

Erivedge vismodegib: Phase Ib data

Erivedge vismodegib: Phase II data

Vismodegib: in locally advanced or metastatic Basal cell carcinoma.

Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC...

Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.

A rapid equilibrium dialysis (RED) assay followed by a solid phase extraction (SPE) high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) assay for the quantitative determination...

Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein.

We studied whether nephrotoxic drug administration sensitizes to acute renal failure (ARF) by administering a sub-nephrotoxic dose of gentamicin. This pre-treatment sensitized animals with no sign of...

Inhibiting the hedgehog pathway in patients with the Basal-cell nevus syndrome.

Background Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objec...

Vismodegib in advanced Basal-cell carcinoma.

To the Editor: Sekulic et al. (June 7 issue)(1) report that "vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma." In this study, all pat...